ArticleJournal of cardiovascular electrophysiology2026
Catheter Ablation Is Associated With a Decrease in Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Atrial Fibrillation and Obstructive Sleep Apnea.
Article in Journal of cardiovascular electrophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Obstructive Sleep Apnoea and Atrial Fibrillation: Current Evidence and Emerging Research Directions.Reviews in cardiovascular medicine · 2026Review
- Additional Stroke Risk Factors Beyond the CHAJournal of clinical medicine · 2026Article
- Sodium-Glucose Cotransporter 2 Inhibitors: An Emerging Therapeutic Approach for Ischemic Stroke Management.CNS drugs · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObstructive sleep apnea (OSA) is a common risk factor for the development and progression of atrial fibrillation (AF). Whether catheter ablation for AF management in patients with coexisting OSA yields survival benefit remains unclear. This study aimed to assess the association of catheter ablation with the incidence of major cardiovascular events (MACE) and all-cause mortality in patients with AF and OSA.
methodsThis was a retrospective cohort study using the TriNetX electronic health record (EHR) database, a global, federated clinical research network aggregating de-identified patient data from multiple healthcare organizations. The study was conducted using real-world data collected from community-based healthcare institutions contributing to the TriNetX network. This multicenter, population-based dataset includes both primary care and referral center data from across the United States and internationally. Adult patients diagnosed with both AF and OSA between November 2014 and November 2024 were included. Patients entered the study at the time of AF diagnosis, with follow-up beginning 3 months later. A total of 18,324 patients were included after 1:1 propensity score matching, 9162 who underwent catheter ablation and 9162 who did not. Matching was performed based on over 30 clinical and demographic variables, including age, sex, body mass index, comorbidities, medications (e.g., anticoagulation), CPAP prescription, echocardiographic data, and laboratory values. Participants were selected using a convenience sampling method from those available in the database, with inclusion contingent on complete data and fulfillment of eligibility criteria. Data on refusals or exclusions were not available due to the nature of de-identified secondary EHR data.
resultsOver a median follow-up of 807 days, 687 MACE events and 438 all-cause mortality events were recorded. Catheter ablation was associated with a significantly reduced risk of MACE (HR: 0.596, 95% CI: 0.510-0.697) and all-cause mortality (HR: 0.264, 95% CI: 0.208-0.335). It was also associated with reduced risk of specific cardiovascular outcomes, including heart failure (HR: 0.376, 95% CI: 0.283-0.501), cerebrovascular disease (HR: 0.492, 95% CI: 0.348-0.696), and cerebral infarction (HR: 0.390, 95% CI: 0.207-0.733).
conclusionCatheter ablation in patients with AF and OSA is associated with a reduced risk of MACE, all-cause mortality, heart failure, and thromboembolic events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.